Home News Sotatercept Could Be a Promising Novel Agent for Pulmonary Arterial Hypertension back to News
minute read
Sotatercept, a novel, first-in-class fusion protein therapy, significantly improved pulmonary-vascular, cardiovascular, and exercise-related outcomes in patients with pulmonary arterial hypertension (PAH) at 24 weeks, according to findings from the PULSAR trial.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
